According to CRI’s market research, the sales value of Anlotinib in the Chinese market increases year by year from 2018 to 2020. Especially in 2019, sales reached CNY 650 million, an increase of about 20 times year on year. The main reason is that Anlotinib has been welcomed by hospitals and patients based on its therapeutic advantages since its approval in 2018. The CAGR of the sales value of Anlotinib in the Chinese market is 444.49% from 2018 to 2020.

CRI predicts that the sales of Rotinib in the Chinese market will continue to grow from 2021 to 2025, with the increase in the number of cancer patients. Lung cancer is the leading cause of human cancer deaths, accounting for about one-fifth of all cancer deaths. According to the data on the number of new cancers in 2020 released by WHO, the number of new lung cancers and deaths in China in 2020 is 280,000 and 710,000, respectively, which are the highest in the world. Anlotinib-treated non-small cell lung cancer (NSCLC) accounts for 80% to 90% of lung cancer in China. The huge patient population will continue to expand the market of Anlotinib. In addition, the increase in indications will also increase sales. In the first half of 2021, Focavi’s fourth indication is in the state of approval in China. It is expected that with the approval of new indications in the future, the patient population of Anlotinib will expand, and sales value and sales volume will also increase to a certain extent.

Topics Covered:
-The impact of COVID-19 on China’s Anlotinib market
– Sales value of China’s Anlotinib 2016-2020
– Competitive landscape of China’s Anlotinib market
– Prices of Anlotinib in China
– Prices of Anlotinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Anlotinib market
– Prospect of China’s Anlotinib market from 2021 to 2025

The post Investigation Report on China’s Anlotinib Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Doxorubicin in the Chinese market has increased year by year from 2016 to 2020. Especially, the sales of Doxorubicin in the Chinese market reached CNY 855 million in 2019, a year-on-year increase of 69.75%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020. The CAGR of Doxorubicin’s sales value in the Chinese market is 38.60% from 2016 to 2020.

CRI expects that with the increase of cancer patients in 2021-2025, the sales volume of Doxorubicin in the Chinese market will increase steadily. Doxorubicin liposome injection has the advantages of targeting, sustained release, and reduced toxicity. Based on these advantages, the sales volume and sales of Doxorubicin liposome injection will continue to increase. In addition, the alleviation of the COVID-19 epidemic will also cause the sales of Doxorubicin to show a recovery growth.

Topics Covered:
-The impact of COVID-19 on China’s Doxorubicin market
– Sales value of China’s Doxorubicin 2016-2020
– Competitive landscape of China’s Doxorubicin market
– Prices of Doxorubicin in China
– Prices of Doxorubicin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Doxorubicin market
– Prospect of China’s Doxorubicin market from 2021 to 2025

The post Investigation Report on China’s Doxorubicin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Goserelin in the Chinese market has increased year by year since 2016-2020, with the CAGR from 2016 to 2019 is around 18%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the annual growth rate of Goserelin’s sales value dropped to 8.76% in 2020. However, the sales value of Goserelin in the Chinese market reached CNY990 million in 2020 and the CAGR of the sales value of Goserelin in the Chinese market is 15.94% from 2016 to 2020.

CRI predicts that with the increase in the number of patients with indications, the sales volume of Goserelin will steadily increase from 2021 to 2025. In 2020, the number of new breast cancers worldwide reached 2.26 million, and the number of prostate cancers was 1.41 million, both of which were on the rise. Therefore, the sales volume of Goserelin for the treatment of breast cancer and prostate cancer increased with the increase in the number of patients diagnosed with breast cancer and prostate cancer, and its sales also increased. China has approved Luye Pharmaceuticals to conduct generic drug clinical trials and has successfully conducted Phase III clinical trials at the end of 2020. It is expected that the generic drug will be launched in the next five years. As a result, the price of Goserelin will continue to fall, sales and sales volume will also have certain upside potential. In addition, the effective alleviation of COVID-19 will also cause a recovery growth in the sales of Goserelin.

Topics Covered:
-The impact of COVID-19 on China’s Goserelin market
– Sales value of China’s Goserelin 2016-2020
– Competitive landscape of China’s Goserelin market
– Prices of Goserelin in China
– Prices of Goserelin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Goserelin market
– Prospect of China’s Goserelin market from 2021 to 2025

The post Investigation Report on China’s Goserelin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Docetaxel in the Chinese market remained constant from 2016 to 2019. Due to the impact of the COVID-19 epidemic on China’s hospital’s overall diagnosis and treatment services, the sales value of Docetaxel in the Chinese market decreased to CNY1.112 billion in 2020, a year-on-year decrease of 16.79%. The CAGR of the sales value of Docetaxel in the Chinese market from 2016 to 2020 was -3.86%.

CRI expects that with the alleviation of the COVID-19 epidemic, sales of Docetaxel will have a restorative growth from 2021 to 2025. In addition, 4.57 million new cancer cases were diagnosed in China in 2020, and the overall cancer incidence increased by about 3.9% annually. Therefore, the sales volume of Docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase with the increase of colon cancer patients and there is room for sales to rise. At the same time, compared with similar drugs, Docetaxel is safer and more effective, the sales volume will grow in the future.

Topics Covered:
-The impact of COVID-19 on China’s Docetaxel market
– Sales value of China’s Docetaxel 2016-2020
– Competitive landscape of China’s Docetaxel market
– Prices of Docetaxel in China
– Prices of Docetaxel in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Docetaxel market
– Prospect of China’s Docetaxel market from 2021 to 2025

The post Investigation Report on China’s Docetaxel Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Oxaliplatin in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 epidemic on the hospital’s overall diagnosis and treatment services, the sales value of Oxaliplatin in the Chinese market decreased to CNY1.165 billion in 2020. The CAGR of Oxaliplatin’s sales value in the Chinese market from 2016 to 2020 was 4.29%.

CRI expects that Oxaliplatin sales will have a restorative growth in 2021-2025 as the alleviation of the COVID-19 epidemic. In 2020, the number of new colon cancer cases in China was 550,000, with an increase of 46.28% from 376,000 in 2018. Therefore, Oxaliplatin sales will increase from 2016 to 2020 with the increase in the number of colon cancer patients.

Topics Covered:
-The impact of COVID-19 on China’s Oxaliplatin market
– Sales value of China’s Oxaliplatin 2016-2020
– Competitive landscape of China’s Oxaliplatin market
– Prices of Oxaliplatin in China
– Prices of Oxaliplatin in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Oxaliplatin market
– Prospect of China’s Oxaliplatin market from 2021 to 2025

The post Investigation Report on China’s Oxaliplatin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, since Pertuzumab entered the Chinese market, the sales grew rapidly, from CNY21.15 million in 2019 to CNY501.69 million in 2020. The annual growth rate of Pertuzumab’s sales is 2272.15%.

CRI expects that based on the price reduction of Pertuzumab, its sales volume will continue to grow from 2021 to 2025. Pertuzumab was included in the medical insurance reimbursement catalog at the beginning of 2020, and the price of each 0.42g dose reduced from CNY18,800 to CNY4955. This price is valid until the end of 2021. The price of Pertuzumab is expected to be lowered again in the future. The price reduction will reduce the burden on patients, thereby increasing the usage rate of Pertuzumab and its sales. At the same time, the huge patient population will also enable the Pertuzumab market to continue to expand. Breast cancer is one of the top ten new cancer cases in China in 2020, reaching 420,000. Among them, HER2-positive patients accounted for 20%-30%. A large number of patients has also increased the demand for Pertuzumab. In addition, the effectiveness of the combination therapy of Pertuzumab and Trastuzumab has also laid down its potential in the market.

Topics Covered:
-The impact of COVID-19 on China’s Pertuzumab market
– Sales value of China’s Pertuzumab 2016-2020
– Competitive landscape of China’s Pertuzumab market
– Prices of Pertuzumab in China
– Prices of Pertuzumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Pertuzumab market
– Prospect of China’s Pertuzumab market from 2021 to 2025

The post Investigation Report on China’s Pertuzumab Market 2021-2025 first appeared on CRI Report.